Back

Increase of HF re-admission rate by chronic administration of tolvaptan for the tolvaptan non-responders.

21 May 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Diuretics and fluid status management Diuretics HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Doctor Kei Tsukamoto

Tokyo Women's Medical University, Tokyo (Japan)

9 More presentations in this session

Presentation thumbnail
Heart failure with preserved ejection fraction: does the intra-venous diuretic treatment duration matter?
Doctor J. Ribeiro (Porto, PT)
Abstract Slides
Presentation thumbnail
Blood purification in end-stage heart failure: a study in 16 patients
Presentation thumbnail
What are predictive factors for body weight loss in patients with acute decompensated heart failure added an oral aquaretic, tolvaptan ?
Doctor T. Ando (Nishinomiya, JP)
Abstract
Presentation thumbnail
Discontinuation of diuretic therapy is safe in accurately selected patients with chronic heart failure and severely reduced ejection fraction: a prospective cohort study in the outpatients setting
Doctor C. Mina (Palermo, IT)
Abstract Slides
Presentation thumbnail
Influence of clinical severity on the association of loop diuretic dose with mortality in patients with heart failure: insights from the unite-hf registry
Doctor K. Adams Jr (Chapel Hill, US)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Diuretics and fluid status management

The Event

Event poster

HEART FAILURE 2016

21 May - 24 May 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources